Table 4. Pharmacokinetic parameters of 5-FU, FT, and CDHP according to CYP2A6 genotype.
| CYP2A6 *1 homozygote | Single-variant of CYP2A6 | Double-variant of CYP2A6 | Point estimate ratio (90% confidence interval) a | |
|---|---|---|---|---|
| 5-FU | ||||
| Cmax (ng ml−1) | 218.1±95.88 | 144.5±43.35 | 138.1±70.03 | 0.70 (0.55–0.88) |
| AUC0–24 h (hng ml−1) | 1295±590.4 | 875.5±303.0 | 1154±1262 | 0.74 (0.56–0.98) |
| FT | ||||
| Cmax (ng ml−1) | 2095±497.0 | 2398±559.1 | 2691±948.2 | 1.17 (1.02–1.33) |
| AUC0–24 h (hng ml−1) | 20770±6831 | 27060±5101 | 32380±14650 | 1.37 (1.19–1.58) |
| CDHP | ||||
| Cmax (ng ml−1) | 28.23±10.44 | 30.32±15.62 | 39.73±24.55 | 1.06 (0.80–1.40) |
| AUC0–24 h (hng ml−1) | 203.4±46.83 | 213.5±125.6 | 208.1±132.4 | 0.93 (0.72–1.20) |
| 5-FU/FT | ||||
| Cmax | 0.1083±0.0494 | 0.0618±0.0195 | 0.0526±0.0205 | 1.67 (1.31–2.13) |
| AUC0–24 h | 0.0710±0.0433 | 0.0327±0.0100 | 0.0348±0.0315 | 1.85 (1.37–2.49) |
Abbreviations: FT=tegafur; Cmax=maximum plasma concentration; AUC0–24 h=area under the plasma concentration-time curve from time 0–24 h; 5-FU/FT=ratio between the pharmacokinetic parameters of 5-FU and FT.
a
Point estimate ratio between single or double variant and *1 homozygote. Individual pharmacokinetic parameters are expressed as means±s.d.